share_log

Global Viscosupplementation System Market Report 2021: Growing Demand for Minimally Invasive Procedures

Global Viscosupplementation System Market Report 2021: Growing Demand for Minimally Invasive Procedures

2021年全球粘液補充系統市場報告:對微創手術日益增長的需求
PR Newswire ·  2021/09/24 07:50

DUBLIN, Sept. 24, 2021 /PRNewswire/ -- The "Viscosupplementation System Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.

都柏林9月2021年2月24日/美通社/--《Viscosupplementation System Market 2021-2027》報告新增至Research andMarkets.com的獻祭。

The global viscosupplementation market is anticipated to grow at a CAGR of around 8.6%

全球粘性補給市場預計將以8.6%左右的複合年增長率增長

The rising global prevalence of knee osteoarthritis, the demand for minimally invasive procedures, and the growing geriatric population are some key factors that are projected to boost the viscosupplementation market during the forecast period. Furthermore, improved healthcare infrastructure and increased awareness about viscosupplementation are expected to provide significant growth to the global viscosupplementation market.

全球膝骨性關節炎患病率的上升,對微創手術的需求,以及老年人口的增長,是預計在預測期內提振粘液補充市場的一些關鍵因素。此外,醫療基礎設施的改善和人們對粘性補充認識的提高,預計將為全球粘性補充市場帶來顯著增長。

On the other hand, the global viscosupplementation market is projected to hinder by stringent government regulations and increasing insurance denials for viscosupplementation products.

另一方面,全球粘性補充市場預計將受到嚴格的政府監管和越來越多的粘性補充產品拒絕保險的阻礙。

However, due to the treatment effectiveness in providing relief to patients, the market for viscosupplementation in knee osteoarthritis is rapidly increasing. Patients who didn't recover from physical exercise, weight loss, or corticosteroid injections will benefit from viscosupplementation for knee procedures. As a result, this will be creating an opportunity for the growth of the market.

然而,由於治療對緩解患者的有效性,膝關節骨關節炎粘性補充術的市場正在迅速增加。那些沒有從體育鍛煉、減肥或皮質類固醇注射中恢復的患者將從膝關節手術的粘性補充中受益。因此,這將為市場的增長創造機會。

Segmental Outlook

細分展望

The global viscosupplementation market is segmented based on product and application. Based on product the market is segmented into single-injection, three-injection, and five-injection. Further on the basis of application, the market is classified into Knee, Hip, Ankle, and others.

全球粘性補給市場根據產品和應用進行細分。根據產品的不同,市場分為一次注射、三次注射和五次注射。根據應用情況,進一步將市場分為膝部、髖部、踝部和其他。

Among product segments, the three-injection segment is projected to have significant growth in the global viscosupplementation market due to the availability of a large number of commercialized goods and a high rate of product adoption.

在產品細分市場中,由於大量商業化商品的供應和高產品採用率,預計三注塑細分市場在全球粘性補給市場將有顯著增長。

This injection supports treating osteoarthritis, a Knee arthritis is a common form of arthritis that affects many people. It is caused when the cartilage, the smooth lining that covers the bones in the joints, breaks down. This injection is suitable for people who did not get relief from nonsteroidal anti-inflammatory drugs or people who can't take drugs due to their side effects.

這種注射劑支持治療骨關節炎,膝關節炎是一種常見的關節炎,影響許多人。它是由軟骨(覆蓋關節中骨骼的光滑襯裏)破裂引起的。這種注射劑適用於未從非甾體抗炎藥中獲得緩解的人,或因副作用而不能服藥的人。

Regional Outlooks

區域展望

The global viscosupplementation market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to have a significant share in the global viscosupplementation market due to rising incidences of osteoarthritis in the US and Canada.

基於包括北美在內的地理位置,全球粘性補給市場被進一步細分,歐洲、亞太地區和世界其他地區。北美由於美國和加拿大骨關節炎發病率的上升,預計將在全球粘性補充市場佔有相當大的份額。

The growing demand for minimally invasive viscosupplementation procedures for the treatment of knee osteoarthritis is also responsible for the market growth in the region. Furthermore, the existence of advanced healthcare infrastructure, the presence of major key players, and the demand for viscosupplementation products are likely to propel the regional market.

對治療膝骨性關節炎的微創粘性補充術的需求不斷增長也是該地區市場增長的原因。此外,先進的醫療基礎設施的存在,主要關鍵參與者的存在,以及對粘性補充產品的需求,可能會推動該地區市場的發展。

Asia-Pacific is projected to have significant growth in the market during the forecast period. The growth is attributed to the upgrade of healthcare facilities and infrastructure in emerging economies such as China, South Korea, and India.

預計亞太地區的市場在預測期內將有顯著增長。這一增長歸因於新興經濟體醫療設施和基礎設施的升級,如中國、韓國和印度.

Furthermore, factors such as increased awareness of the effectiveness of viscosupplementation and demand for non-surgical procedures are projected to propel market growth. Furthermore, the relatively low regulatory barriers in South Korea and other emerging countries are expected to draw industry players looking to establish a presence in these emerging markets.

此外,人們對粘性補充劑有效性的認識增強以及對非手術程序的需求等因素預計將推動市場增長。此外,韓國和其他新興國家的監管門檻相對較低,預計將吸引尋求在這些新興市場建立業務的行業參與者。

Key Topics Covered:

涵蓋的主要主題:

1. Report Summary

1.報告彙總

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulations

2.市場概況和洞察力2.1.報告的範圍2.2.分析師洞察與當前市場趨勢2.2.1.主要調查結果2.2.2.建議2.2.3.結論2.3.條例

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players

3.競爭格局3.1.重點企業分析3.1.1。概述3.1.2。財務分析3.1.3.SWOT分析3.2.關鍵戰略分析3.3.新冠肺炎對主要玩家的影響

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

4.市場決定因素4.1.激勵因素4.2.約束4.3.機遇

5. Market Segmentation
5.1. Global Viscosupplementation Market by Product
5.1.1. Single-Injection
5.1.2. Three-Injection
5.1.3. Five-Injection
5.2. Global Viscosupplementation Market by Application
5.2.1. Knee
5.2.2. Hip
5.2.3. Ankle
5.2.4. Others(Shoulder, Spine)

5.市場細分5.1.按產品劃分的全球視頻補給市場5.1.1.單次注射5.1.2。三針注射5.1.3.五針5.2.按應用劃分的全球視頻補給市場5.2.1.膝5.2.2。臀部5.2.3.腳踝5.2.4。其他(肩部、脊椎)

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

6.區域分析6.1.北美6.1.1. 美國6.1.2.加拿大6.2. 歐洲6.2.1。英國6.2.2.德國6.2.3. 意大利6.2.4.西班牙6.2.5. 法國6.2.6.歐洲其他國家6.3. 亞太6.3.1。中國6.3.2. 印度6.3.3。日本6.3.4. 韓國6.3.5。亞太地區其他地區6.4.世界其他地區

7. Company Profiles
7.1. Anika Therapeutics, Inc.
7.2. Ferring B.V.
7.3. Fidia Farmaceutici S.p.A
7.4. Johnson & Johnson Services, Inc.
7.5. KalVista Pharmaceuticals, Inc.
7.6. LG Chem (Life Sciences)
7.7. Lifecore Biomedical, LLC
7.8. Maxigen Biotech, Inc.
7.9. Pharmascience Inc.(PendoPharm)
7.10. Regen Lab SA
7.11. Sanofi S.A.
7.12. Seikagaku Corp.
7.13. Shanghai Haohai Biological Technology Co., Ltd.
7.14. Smith & Nephew PLC
7.15. Stellar Pharmaceuticals, Inc.
7.16. Stryker Corp.
7.17. Swiss Biomed Orthopaedics AG
7.18. Virchow Biotech Pvt. Ltd.
7.19. Zimmer Biomet Holdings, Inc.

7.公司簡介7.1.安妮卡治療公司7.2.費林B.V.7.3.Fidia FarmPharmtici S.p.A7.4.強生服務有限公司7.5.卡爾維斯塔製藥公司(KalVista PharmPharmticals,Inc.)7.6.LG化學(LG Chem)(生命科學)7.7.LifeCore生物醫學有限責任公司7.8.Maxigen Biotech,Inc.7.9.藥學公司(Pharmascience Inc.)7.10.Regen Lab SA7.11。賽諾菲公司(Sanofi S.A.)7.12。精工株式會社7.13.上海浩海生物科技有限公司。7.14.Smith&Nephew PLC7.15。星辰製藥公司7.16。史崔克公司(Stryker Corp.)7.17.瑞士Bied Orthopedics公司7.18。Virchow Biotech Pvt.Ltd.(Virchow Biotech Pvt.Ltd.)7.19.齊默爾生物科技控股公司(Zimmer Biomet Holdings,Inc.)

For more information about this report visit https://www.researchandmarkets.com/r/ssdjf4

有關本報告的更多信息,請訪問https://www.researchandmarkets.com/r/ssdjf4。

Media Contact: 
Research and Markets
Laura Wood, Senior Manager
[email protected]      

媒體聯繫人: 研究和市場勞拉·伍德(Laura Wood),高級經理[受電子郵件保護]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

對於E.S.T辦公時間,請撥打電話:+1-917-300-0470美國/加拿大免費電話:+1-800-526-8630對於格林尼治標準時間辦公時間,請致電+353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

美國傳真:646-607-1904傳真(美國境外):+353-1-481-1716

SOURCE Research and Markets

來源研究和市場

Related Links

相關鏈接

http://www.researchandmarkets.com

Http://www.researchandmarkets.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論